MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Deferred Tax Assets / Liabilities | ₹8.67 Cr | ₹48 Cr | ₹16 Cr | ₹-36 Cr | ₹-40 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of MANKIND PHARMA ?
Year | Deferred Tax Assets / Liabilities |
---|---|
Mar2024 | ₹8.67 Cr |
Mar2023 | ₹48 Cr |
Mar2022 | ₹16 Cr |
Mar2021 | ₹-36 Cr |
Mar2020 | ₹-40 Cr |
How is Deferred Tax Assets / Liabilities of MANKIND PHARMA Trending?
Years | Deferred Tax Assets / Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹8.67 Cr | -81.76 | |
Mar2023 | ₹48 Cr | 191.02 | |
Mar2022 | ₹16 Cr | Positive | |
Mar2021 | ₹-36 Cr | Negative | |
Mar2020 | ₹-40 Cr | - |
Compare Deferred Tax Assets / Liabilities of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹101,468.7 Cr | -4.1% | -14.4% | 17% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹428,461.0 Cr | 1.4% | -4.1% | 32.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹147,983.0 Cr | -4.2% | -5.1% | 59.6% | Stock Analytics | |
CIPLA | ₹112,735.0 Cr | -2.2% | -7.3% | 0.2% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,913.9 Cr | -7.1% | -13.8% | 8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹92,815.0 Cr | -6.4% | -5.2% | 31.2% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | -4.1% |
-14.4% |
17% |
SENSEX | -2.2% |
-4% |
5.5% |
You may also like the below Video Courses